On Dec. 22, 2020, Abivax announced that the Companyﾒs ongoing ABX464 phase 2b/3 trial in high-risk Covid-19 patients (miR-AGE) had been declared a ﾓResearch National Priorityﾔ by the French government steering committee for therapeutic clinical trials and other research (CAPNET).

The Research National Priority designation also incentivizes clinical investigators to prioritize enrollment of their patients in these clinical trials and may provide institutional financing of these clinical studies.